BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease 8th April 2021 (Last Updated April 8th, 2021 18:15)
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
The trial plans to enrol ten patients in the US and Canada. Credit: National Institute on Aging, National Institutes of Health.
Share Article
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
A progressive neurodegenerative disorder, PD is caused by damage to nerve cell in the brain, causing lower dopamine levels. The deterioration of motor and non-motor symptoms is because of dopamine-producing neuron loss.